Compare Incyte Corporation (INCY) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while Direxion Daily FTSE China Bull 3x Shares trades at $28. The key difference: Incyte Corporation is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| INCY | YINN | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $118.52 | $56.62 |
52-Week Low | $67.38 | $21.45 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $28.89, up 7.84% with a bullish technical signal. The leveraged ETF structure amplifies exposure to Chinese equities, which face mixed sentiment amid economic stabilization efforts and US-China tensions. Moving averages show bullish momentum while oscillators remain neutral, with key resistance at $27.
Outlook remains volatile given YINN's 3x leverage structure and China's economic crosscurrents. Investment opportunity exists for tactical traders betting on China's infrastructure and AI stimulus, but risks include geopolitical friction and leveraged decay. The fund's performance hinges on Beijing's policy effectiveness versus US restrictions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
